ACAD (acadia-pharm.com) Company Projected Revenue
Effective distribution channels for ACADIA Pharmaceuticals (ACAD) neuro-drugs provide excellent operating leverage. The future sales volume vector on the GURU.Markets daily chart shows that the current status is 0.59. However, revenues are based on a narrow portfolio of FDA-supervised drugs, and global political fragmentation complicates the international logistics of components and the conduct of global clinical trials.
Financial and market metric breakdowns for ACADIA Corp (ACAD)
- current price and projected stock value:
- business market valuation indicators:
- balance sheet equity data:
- company total debt and liquidity indicators:
Debt to Equity ACADIA Pharmaceuticals|ACAD - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity acadia-pharm.com|ACAD - Company Total Debt|Debts to Book Capitalization ACADIA Pharmaceuticals Inc|ACAD - Company Long-Term Debts|Company Short-Term Debts ACADIA Pharmaceuticals|Quick Ratio acadia-pharm.com
- earnings and market ratios statistics:
ACAD - Company Net Income|Future Profit ACADIA Pharmaceuticals|ACAD - P/E Multiple|Projected Price to Earnings ACADIA Pharmaceuticals Inc.|ACAD - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple ACADIA Pharmaceuticals Inc.|ACAD - Operating income before deduction of amortization|Net earnings per share (EPS TTM) ACADIA Pharmaceuticals|ACAD - Net earnings per share for the last 12 months|Quarterly EPS earnings growth acadia-pharm.com|ACAD - Earnings growth in current year|Net earnings per share growth forecast for next year ACADIA Pharmaceuticals
- sales volume and revenue information:
Fundamental company analysis:acadia-pharm.com
To objectively measure the operational success of ACADIA Pharmaceuticals (ACAD), investors must track real market demand trends that lead quarterly financial reports. The company's projected sales metric mathematically eliminates the time lag, reflecting the expansion potential of Daybue and the stability of Nuplazid, which allows this chart to assess the asset's fundamental value without the influence of market noise or emotional volatility.
Analysis of competing companies
Company Future Sales Volume BIIB (Biogen)|NBIX (Neurocrine Biosciences, Inc.) - Company Future Revenue|Company Projected Revenue Regencell RGC|Company Projected Revenue Volume AXSM (Axsome Therapeutics Inc)|Xenon Corp - Projected Sales Volume|Company Future Revenue VKTX (Viking Therapeutics)|Supernus Pharmaceuticals (SUPN) - Company Projected Revenue|Company Expected Revenue CPRX (Catalyst Pharmaceuticals, Inc.)|Company Projected Revenue Denali Therapeutics Inc|Company Expected Sales Volume Harmony Corp HRMY|Projected Sales Volume BHVN|Company Future Sales Volume Amylyx Pharmaceuticals AMLX|Projected Sales Volume TRVI (Trevi Corp)|Company Future Sales Praxis Precision Medicines, Inc. (PRAX)|Anavex Life Sciences Corp - Projected Sales Volume|CeriBell Corp (CBLL) - Company Future Sales Volume|Prothena Corp (PRTA) - Company Projected Revenue|Company Expected Sales Volume Alector Inc. (ALEC)|Company Future Sales Volume ANNX|omeros.com (OMER) - Company Future Sales|Company Projected Revenue Neurogene Inc. (NGNE)|ACIU (AC Immune Inc) - Company Future Revenue|Projected Sales Volume VYGR (voyagertherapeutics.com)|Company Future Sales Neumora Therapeutics (NMRA)|SCLX - Company Projected Revenue|Company Sales Forecast Tevogen Bio Holdings Inc. (TVGN)|Alpha Cognition (ACOG) - Company Projected Revenue|CGTX - Company Future Sales|IKT (inhibikase.com) - Projected Sales Volume|cassavasciences.com (SAVA) - Company Future Sales|Company Future Sales Volume ASRT (Assertio Therapeutics)|Company Future Sales Coya Therapeutics|Vistagen - Company Future Sales Volume|ovidrx.com (OVID) - Company Expected Sales Volume|Acumen Pharmaceuticals - Projected Sales Volume|Company Expected Sales Volume cervomed.com|ATHE: Projected Sales Volume|Clene Inc - Company Future Revenue|Company Projected Revenue PepGen|JUNS (Jupiter Neurosciences Inc) - Company Projected Revenue Volume|Company Future Sales Volume RLMD (Relmada Corp)|annovisbio.com - Company Revenue Forecast|Company Projected Revenue gracetx.com GRCE|AIFF (Firefly Neuroscience, Inc.) - Company Expected Revenue|KLTO - Company Projected Revenue|Company Expected Sales Volume NeuroSense Therapeutics Ltd|Reviva Pharmaceuticals (RVPH) - Company Projected Revenue|Company Revenue Forecast MTVA|Company Future Sales Volume NRXS|Company Future Sales Volume Helius Medical (HSDT)|Projected Sales Volume PASG|Neuphoria Therapeutics - Company Revenue Forecast|Company Projected Revenue Minerva Neurosciences, Inc. NERV|Projected Sales Volume Athira Pharma ATHA|ADXN: Company Future Sales Volume|Company Expected Sales Volume Alzamend Neuro|Cyclerion Therapeutics Inc. (CYCN) - Company Projected Revenue|Company Expected Sales Volume Protagenic Therapeutics (PTIX)|KTTA (pasitheaclinics.com) - Projected Sales Volume|Company Future Sales Volume Cortigent (CRGT)|Projected Sales Volume ATXI|BCLI - Company Expected Sales Volume|Projected Sales Volume CARA (Cara Therapeutics, Inc)|Chromocell Therapeutics Corporation (CHRO) - Company Expected Sales Volume|ELYM - Company Projected Revenue|Company Sales Forecast intracellulartherapies.com (ITCI)|Longboard (LBPH) - Company Projected Revenue|Marinus Pharmaceuticals Inc - Company Future Revenue|Company Future Sales Volume NKGN|NeuroBo - Company Expected Revenue|Company Projected Revenue Sage Therapeutics, Inc (SAGE)|Company Future Sales Volume Synaptogenix SNPX|Trevena, Inc. - Company Future Sales Volume|VIGL: Company Revenue Forecast|WENA: Company Future Sales Volume|Company Expected Sales Volume Cerevel Therapeutics
